---
figid: PMC9331826__molecules-27-04750-g003
figtitle: Epithelial–Mesenchymal Transition-Mediated Tumor Therapeutic Resistance
organisms:
- Homo sapiens
- Mus musculus
- Curcuma longa
pmcid: PMC9331826
filename: molecules-27-04750-g003.jpg
figlink: /pmc/articles/PMC9331826/figure/molecules-27-04750-f003/
number: F3
caption: 'Mechanism of EMT-mediated targeting and immunotherapy resistance: Tumor-associated
  genes can induce EMT-mediated tumor cell targeting and immunotherapy resistance.
  LINC00460 can competitively inhibit the expression of Mir-149-5p and induce EMT
  by regulating the expression of IL-6, thus mediating gefitinib resistance. Mir-625-3p
  inhibited the expression of target gene AXL and activated the TGF-β/Smad signaling
  pathway to induce EMT. Mir-141-3p can inhibit the expression of target gene EGFR
  and induce EMT, thus mediating the resistance of gefitinib and cetuximab. Tumor-associated
  proteins (Oct4, Nanog, and TGF-β1) can induce EMT through related signaling pathways
  (Wnt/β-catenin and ITGβ3) and mediate gefitinib resistance. Tumor-associated proteins
  (TNF-α, TGF-β1, and DCLK1) can induce EMT through related signaling pathways (NF-κB
  and YAP), thereby mediating immunotherapy resistance.'
papertitle: Epithelial–Mesenchymal Transition-Mediated Tumor Therapeutic Resistance.
reftext: Zhimin Xu, et al. Molecules. 2022 Aug;27(15):4750.
year: '2022'
doi: 10.3390/molecules27154750
journal_title: Molecules
journal_nlm_ta: Molecules
publisher_name: MDPI
keywords: EMT | chemoresistance | radioresistance | targeted therapy | immunity therapy
automl_pathway: 0.9583892
figid_alias: PMC9331826__F3
figtype: Figure
organisms_ner:
- Homo sapiens
- Mus musculus
redirect_from: /figures/PMC9331826__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9331826__molecules-27-04750-g003.html
  '@type': Dataset
  description: 'Mechanism of EMT-mediated targeting and immunotherapy resistance:
    Tumor-associated genes can induce EMT-mediated tumor cell targeting and immunotherapy
    resistance. LINC00460 can competitively inhibit the expression of Mir-149-5p and
    induce EMT by regulating the expression of IL-6, thus mediating gefitinib resistance.
    Mir-625-3p inhibited the expression of target gene AXL and activated the TGF-β/Smad
    signaling pathway to induce EMT. Mir-141-3p can inhibit the expression of target
    gene EGFR and induce EMT, thus mediating the resistance of gefitinib and cetuximab.
    Tumor-associated proteins (Oct4, Nanog, and TGF-β1) can induce EMT through related
    signaling pathways (Wnt/β-catenin and ITGβ3) and mediate gefitinib resistance.
    Tumor-associated proteins (TNF-α, TGF-β1, and DCLK1) can induce EMT through related
    signaling pathways (NF-κB and YAP), thereby mediating immunotherapy resistance.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - LINC00460
  - IL6
  - POU5F1
  - POU5F1P3
  - POU5F1P4
  - NANOG
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - CTNNB1
  - ITK
  - SLC22A3
  - TGFB1
  - AQP3
  - AXL
  - SMAD1
  - SMAD4
  - SMAD5
  - SMAD6
  - SMAD7
  - SMAD9
  - SMAD2
  - SMAD3
  - TGFB2
  - TGFB3
  - EGFR
  - TNF
  - NFKB1
  - DCLK1
  - YAP1
  - Il6
  - Pou5f1
  - Nanog
  - Ctnnb1
  - Itk
  - Slc22a3
  - Tgfb1
  - Axl
  - Ltbp1
  - Egfr
  - Tnf
  - Nfkb1
  - Dclk1
  - Yap1
---
